May 30, 2018
Sachs Immuno-Oncology BD&L and Investment Forum and 2018 BIO International Convention AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack...
Read More >>
May 30, 2018
Dr. Jonathan Bramson to be presenting at 3:20 p.m. CT on June 1. At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as...
Read More >>
May 30, 2018
Triumvira President and Chief Executive Officer, Dr. Paul Lammers available for private meetings June 4-5 At BIO International, Triumvira Immunologics President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June...
Read More >>
May 17, 2018
Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack...
Read More >>
May 2, 2018
AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack multiple cancers, today announced a strategic relationship with the...
Read More >>
